benzbromarone

ApprovedSmall molecule

AstraZeneca

benzbromarone is one of 51 small molecule programs targeting Hyperuricemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperuricemiaActive, not recruiting

Left Ventricular Diastolic DysfunctionActive, not recruiting

Heart FailureActive, not recruiting

HyperuricemiaPhase 2

Active, not recruiting

Left Ventricular Diastolic DysfunctionApproved

Active, not recruiting

Heart FailureApproved

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

benzbromarone

AstraZeneca

Approved

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Medrol

Pfizer

Preclinical

1 4

Activase

Savaysa

Xylocaine

1 7

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 9

Adriamycin

GGynecologic Oncology Group

Preclinical

—10

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperuricemia4 trials

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03185793·198 enrolled

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

Completed·IInventisBio Co., Ltd·Phase 2·NCT05504083·121 enrolled

A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02317861·110 enrolled

Show 1 more trial

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Completed·FFuji Yakuhin Co., Ltd.·Phase 3·NCT03100318·201 enrolled

MPA1 trial

Compare the Renal Protective Effects of Febuxostat and Benzbromarone

Completed·SShanghai 10th People's Hospital·N/A·NCT02338323·160 enrolled

Acute1 trial

Acute Effects of Benzbromaron on the Pulmonary Circulation

Completed·MMedical University of Graz·Phase 2·NCT02790450·10 enrolled

CKD1 trial

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients

Unknown status·SShanghai 10th People's Hospital·N/A·NCT02944214·800 enrolled

Left ventricular diastolic dysfunction1 trial

Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction

Unknown status·NNational Defense Medical Center, Taiwan·Phase 4·NCT03534037·120 enrolled

1 more indication

Heart Failure1 trial

Treatment of Hyperuricemia in Patients With Heart Failure

Completed·TTottori University Hospital·Phase 4·NCT00422318

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for benzbromarone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — benzbromarone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for benzbromarone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

benzbromarone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperuricemia4 trials

MPA1 trial

Acute1 trial

CKD1 trial

Left ventricular diastolic dysfunction1 trial

Heart Failure1 trial

References

Drug Info

Quick Facts

Related News